hrcak mascot   Srce   HID

Ostalo

TREATMENT OF CHRONIC HEPATITIS C IN HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENTS

JOSIP BEGOVAC   ORCID icon orcid.org/0000-0003-2641-4327 ; Dr. Fran Mihaljević University Hospital for Infectious Diseases, Zagreb, Croatia

Puni tekst: hrvatski, pdf (313 KB) str. 351-359 preuzimanja: 440* citiraj
APA 6th Edition
BEGOVAC, J. (2013). LIJEČENJE KRONIČNOG HEPATITISA C U OSOBA ZARAŽENIH VIRUSOM HUMANE IMUNODEFICIJENCIJE. Acta medica Croatica, 67 (4), 351-359. Preuzeto s https://hrcak.srce.hr/113723
MLA 8th Edition
BEGOVAC, JOSIP. "LIJEČENJE KRONIČNOG HEPATITISA C U OSOBA ZARAŽENIH VIRUSOM HUMANE IMUNODEFICIJENCIJE." Acta medica Croatica, vol. 67, br. 4, 2013, str. 351-359. https://hrcak.srce.hr/113723. Citirano 29.10.2020.
Chicago 17th Edition
BEGOVAC, JOSIP. "LIJEČENJE KRONIČNOG HEPATITISA C U OSOBA ZARAŽENIH VIRUSOM HUMANE IMUNODEFICIJENCIJE." Acta medica Croatica 67, br. 4 (2013): 351-359. https://hrcak.srce.hr/113723
Harvard
BEGOVAC, J. (2013). 'LIJEČENJE KRONIČNOG HEPATITISA C U OSOBA ZARAŽENIH VIRUSOM HUMANE IMUNODEFICIJENCIJE', Acta medica Croatica, 67(4), str. 351-359. Preuzeto s: https://hrcak.srce.hr/113723 (Datum pristupa: 29.10.2020.)
Vancouver
BEGOVAC J. LIJEČENJE KRONIČNOG HEPATITISA C U OSOBA ZARAŽENIH VIRUSOM HUMANE IMUNODEFICIJENCIJE. Acta medica Croatica [Internet]. 2013 [pristupljeno 29.10.2020.];67(4):351-359. Dostupno na: https://hrcak.srce.hr/113723
IEEE
J. BEGOVAC, "LIJEČENJE KRONIČNOG HEPATITISA C U OSOBA ZARAŽENIH VIRUSOM HUMANE IMUNODEFICIJENCIJE", Acta medica Croatica, vol.67, br. 4, str. 351-359, 2013. [Online]. Dostupno na: https://hrcak.srce.hr/113723. [Citirano: 29.10.2020.]

Sažetak
Treatment of HCV infection offers the possibility of viral eradication, thus every person with a detectable HCV viral load is a candidate for treatment. Treatment is recommended to all HCV/HIV co-infected patients with: 1) repeatedly elevated aminotransferase levels; 2) F2 stage of liver fibrosis or higher, regardless of alanine aminotransferase values; and 3) more than 200 CD4+ lymphocytes per μL of blood. Treatment with a combination of pegylated interferon and weight-based ribavirin (1000 mg/day if <75 kg and 1200 mg/day if >75 kg) is recommended. Pegylated interferon is used as 180 μg for the alfa-2a form and 1.5 mg/kg for the alfa-2b form once weekly subcutaneously. HCV RNA should be measured after 4 weeks of treatment, and later as needed, in weeks 12, 24, 48 or 72. For evaluation of a sustained virologic response, HCV RNA should be measured 24 weeks after the end of treatment. Treatment duration for patients who have a rapid viral response (undetectable levels of HCV RNA after 4 weeks of treatment) is 24 weeks (genotypes 2 and 3) or 48 weeks (genotypes 1 and 4). For patients without a rapid virologic response, but with an adequate response after 12 and 24 weeks, we generally recommend treatment for 48 weeks. Treatment discontinuation is recommended for patients with <2 log viral load decline after 12 weeks or with a detectable viral load after 24 weeks of treatment. In HCV genotype 1 infection and F3 or F4 liver fibrosis, treatment with boceprevir or telaprevir in addition to pegylated interferon and ribavirin is recommended. In case of persistent HCV replication during therapy stopping rules should be applied.

Ključne riječi
hepatitis C; hepatitis C virus; human immunodeficiency virus; coinfection; treatment

Hrčak ID: 113723

URI
https://hrcak.srce.hr/113723

[hrvatski]

Posjeta: 619 *